CEVA Stock Analysis: CEVA | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 1.269m USD | 12M Return: 86.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.1M
Qual. Beats: 0
Rev. Trend: 40.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CEVA, Inc. is a fabless semiconductor intellectual property (IP) company that licenses silicon and software IP to chipmakers and OEMs worldwide. Unlike integrated device manufacturers, CEVA does not fabricate chips itself; instead, it earns revenue through upfront licensing fees and per-unit royalties on every device shipped that incorporates its technology, a business model that requires comparatively lower capital expenditure and allows for high operating margins once designs are adopted.
The companys product portfolio centers on wireless connectivity and signal processing, including DSP cores and platforms for 5G, 5G-Advanced, Bluetooth, Wi-Fi, ultra-wideband, and NB-IoT modem SoCs. It also offers audio DSP and noise cancellation IP, sensor fusion software, and a family of neural processing units (NPUs) targeting embedded and generative AI workloads. This positions CEVA within the broader semiconductor IP market, where it competes alongside larger players focused mainly on general-purpose CPU and GPU cores.
Founded in 1999 as ParthusCeva and renamed CEVA in December 2003, the company is headquartered in Rockville, Maryland, and serves customers across the United States, Europe, the Middle East, and the Asia Pacific region.
- 5G baseband IP licensing drives core royalty revenue growth
- Ceva-NeuPro NPU portfolio targets embedded AI market expansion
- China smartphone weakness pressures handset IP royalty stream
| Net Income: -11.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -1.82 > 1.0 |
| NWC/Revenue: 225.6% < 20% (prev 172.2%; Δ 53.40% < -1%) |
| CFO/TA -0.00 > 3% & CFO -837k > Net Income -11.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.7m) vs 12m ago 16.47% < -2% |
| Gross Margin: 87.08% > 18% (prev 87.40%; Δ -0.32% > 0.5%) |
| Asset Turnover: 32.19% > 50% (prev 35.20%; Δ -3.01% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.65 (Total Current Assets 280.9m - Total Current Liabilities 27.4m) / Total Assets 388.2m |
| B: -0.01 (Retained Earnings -4.48m / Total Assets 388.2m) |
| C: -0.02 (EBIT TTM -5.50m / Avg Total Assets 349.1m) |
| D: 6.76 (Book Value of Equity 338.2m / Total Liabilities 50.0m) |
| Altman-Z'' = 11.24 = AAA |
| DSRI: 1.16 (Receivables 48.9m/40.8m, Revenue 112.4m/109.1m) |
| GMI: 1.00 (GM 87.40% / 87.08%) |
| AQI: 0.80 (AQ_t 0.21 / AQ_t-1 0.26) |
| SGI: 1.03 (Revenue 112.4m / 109.1m) |
| TATA: -0.03 (NI -11.8m - CFO -837k) / TA 388.2m) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 16, 2026, the stock is trading at USD 41.96 with a total of 581,900 shares traded. Over the past week, the price has changed by -5.83%, over one month by -13.40%, over three months by +89.44% and over the past year by +86.82%.
Current recommended Stop Loss: 36.90 (which is 12.1% or 1.4 ATR below the current price).
CEVA has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CEVA.
- StrongBuy: 7
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 47 | 12% |
P/E Forward = 89.2857
P/S = 11.2898
P/B = 3.7516
P/EG = 4.4647
Revenue TTM = 112.4m USD
EBIT TTM = -5.50m USD
EBITDA TTM = -1.36m USD
Long Term Debt = 14.1m USD (estimated: total debt 16.9m - short term 2.79m)
Short Term Debt = 2.79m USD (from shortTermDebt, last quarter)
Debt = 16.9m USD (from shortLongTermDebtTotal, last quarter) (leases 16.9m already included)
Net Debt = -198.8m USD (calculated: Debt 16.9m - CCE 215.7m)
Enterprise Value = 1.07b USD (1.27b + Debt 16.9m - CCE 215.7m)
Interest Coverage Ratio = unknown (Ebit TTM -5.50m / Interest Expense TTM 0.0)
EV/FCF = -185.7x (Enterprise Value 1.07b / FCF TTM -5.76m)
FCF Yield = -0.54% (FCF TTM -5.76m / Enterprise Value 1.07b)
FCF Margin = -5.13% (FCF TTM -5.76m / Revenue TTM 112.4m)
Net Margin = -10.47% (Net Income TTM -11.8m / Revenue TTM 112.4m)
Gross Margin = 87.08% ((Revenue TTM 112.4m - Cost of Revenue TTM 14.5m) / Revenue TTM)
Gross Margin QoQ = 85.76% (prev 88.08%)
Tobins Q-Ratio = 2.76 (Enterprise Value 1.07b / Total Assets 388.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 16.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -4.34m (EBIT -5.50m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.26 (Total Current Assets 280.9m / Total Current Liabilities 27.4m)
Debt / Equity = 0.05 (Debt 16.9m / totalStockholderEquity, last quarter 338.2m)
Debt / EBITDA = 146.2 (negative EBITDA) (Net Debt -198.8m / EBITDA -1.36m)
Debt / FCF = 34.50 (negative FCF - burning cash) (Net Debt -198.8m / FCF TTM -5.76m)
Total Stockholder Equity = 302.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.37% (Net Income -11.8m / Total Assets 388.2m)
RoE = -3.89% (Net Income TTM -11.8m / Total Stockholder Equity 302.3m)
RoCE = -1.74% (EBIT -5.50m / Capital Employed (Equity 302.3m + L.T.Debt 14.1m))
RoIC = -1.21% (negative operating profit) (NOPAT -4.34m / Invested Capital 358.0m)
WACC = 14.83% (E(1.27b)/V(1.29b) * Re(15.03%) + D(16.9m)/V(1.29b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 15.03% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 70.11 | Cagr: 6.65%
[DCF] Fair Price = unknown (Cash Flow -5.76m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: 40.80 | Revenue CAGR: 2.72% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=-0.41% | Revisions=-12% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.17 | Chg30d=-0.54% | Revisions=+50% | Analysts=9
EPS current Year (2026-12-31): EPS=0.53 | Chg30d=-0.43% | Revisions=+70% | GrowthEPS=+25.8% | GrowthRev=+11.9%
EPS next Year (2027-12-31): EPS=0.82 | Chg30d=-0.46% | Revisions=+44% | GrowthEPS=+55.2% | GrowthRev=+13.7%
[Analyst] Revisions Ratio: +54% (up=17, down=4)